D
Diabeasy / Clinician
A Caresoft programme
VJ
Atlas/ Clinic Console/ My panel/ Meera Ambekar
MA

Meera Ambekar

F · 51 yr | T2DM · diagnosed Mar '22 · 4 yr | BMI 28.4 | Mumbai, MH | Patient ID: DBS-2026-058472
Novo Care+ enrolled HbA1c 8.9% · uncontrolled Insulin initiation today Comorbidity: dyslipidaemia No DKA history
PSP ACTIVE
Enrolled 12 May 2026
Last seen by you, today 11:45
HbA1c · current
8.9%
▲ 0.3 pp vs Feb
Fasting glucose
186 mg/dL
3-day avg from app
Post-prandial
248 mg/dL
2hr post-lunch
eGFR
94 mL/min
Stage 1 · normal
LDL-C
132 mg/dL
on Atorvastatin 10mg
BP (avg 7d)
128/84
Home monitoring
Weight · BMI
71.4 kg
BMI 28.4 · overweight

HbA1c trajectory · Meera Ambekar

Quarterly measurements · target zone < 7%
10% 9% 8% 7% 6% ADA target zone < 7% 9.2 8.8 8.2 7.8 8.0 8.6 8.9 Trending up Insulin initiation today Q1 '23 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Today
Patient HbA1c ADA target zone
Reading uploaded by Thyrocare Lab · 24 Apr 2026 · result link view PDF

Medication regimen

Current + titration history
Currently prescribed
Tresiba FlexTouch 100 IU/mL
10 units, subcutaneous, OD at bedtime · Refill via Novo Care+ · 28% subsidy
Metformin 1000mg BD
Continued · Aug '22 onwards
Glimepiride 2mg OD
Reduced from 4mg today to manage hypo risk with insulin
Atorvastatin 10mg ON
Lipid management · since Jan '24
Previous changes
15 Mar '24 · Glimepiride increased 2mg → 4mg
04 Aug '22 · Metformin increased 500mg → 1000mg BD
15 Mar '22 · Initial diagnosis · started Metformin 500mg BD
e-Prescribe refill →

Clinical timeline

All clinical events · visits, labs, refills, AEs
12 MAY 2026 · 11:45 IST

Consultation · Dr. V. Joshi · Insulin initiation

HbA1c 8.9% after Q3 lapse · OAD optimisation insufficient. Initiated Tresiba 10u OD with titration plan. Patient enrolled in Novo Care+. Glimepiride reduced 4 → 2mg to manage hypoglycaemia risk. Lifestyle counselling.

PSP enrolment Rx issued
24 APR 2026

HbA1c result · 8.9% · Thyrocare

Trending up from 8.6% in Q3 '25. Triggered system flag for insulin initiation review.

11 FEB 2026

Consultation · Dr. V. Joshi · Routine follow-up

HbA1c 8.6% noted. Advised increased physical activity, dietary review. Continued current OAD regimen with plan to reassess in 90 days.

08 OCT 2025

HbA1c result · 8.6%

First measurement showing loss of glycaemic control. Patient reported irregular medication adherence during summer.

22 MAY 2025

Annual screening · diabetic retinopathy

Result: no retinopathy detected. Fundus images on file. Next screening due May 2026.

15 MAR 2024

Medication adjustment

Glimepiride increased from 2mg to 4mg OD due to rising FPG values. Metformin maintained.

04 MAR 2022

Initial T2DM diagnosis

Presenting HbA1c 9.2%, FPG 168 mg/dL. Started Metformin 500mg BD. Lifestyle counselling provided.

Diabetes screening calendar

ADA / RSSDI 2024 guidelines

Retinopathy screening

Last: 22 May 2025 · clear

Foot examination

Last: 11 Feb 2026 · normal

Lipid panel

Last: 24 Apr 2026

Renal panel · eGFR / UACR

Last: 24 Apr 2026 · 94 mL/min

Dental review

Last: 18 Aug 2023
Schedule labs via programme →
PSP support contacts

Novo Care+ team

PN
Pratiksha Naik, RN
Nurse coach · Marathi/English/Hindi
+91 22 4198 0023 · Mon-Sat 9-7
⏲
24×7 hypo helpline
Toll-free emergency support
1800-209-9090
℞
Refill pharmacy
1mg · Andheri E facility
Next ship: Fri 15 May
RECORD-ID: DBS-2026-058472 ATTENDING: Dr. V. Joshi · MCI 2287/MH LAST-MODIFIED: 12 May 2026 · 11:47 IST
EMR-grade audit trail · All edits time-stamped & signed